Beyond Air Inc
NASDAQ:XAIR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Beyond Air Inc
NASDAQ:XAIR
|
US |
|
Graphic Packaging Holding Co
NYSE:GPK
|
US |
|
Yuanli Chemical Group Co Ltd
SSE:603217
|
CN |
|
B
|
Bay Capital PLC
LSE:BAY
|
JE |
|
S
|
Spinnaker Acquisitions PLC
LSE:SPAQ
|
UK |
Beyond Air Inc
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. The company is headquartered in Garden City, New York and currently employs 45 full-time employees. The company went IPO on 2019-05-07. The firm is engaged in developing a nitric oxide (NO) generator and delivery system through its LungFit platmorfm that is capable of generating NO from ambient air. Its pipeline includes LungFit PH designed to deliver a dosage of NO to the lungs for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN), LungFit PRO for the treatment of viral lung infections for adults, which is commonly caused by rhinovirus, respiratory syncytial virus (RSV) and influenza virus and LungFit GO for the treatment of rare and serious pulmonary disease associated with increased morbidity and mortality called Nontuberculous mycobacteria (NTM) lung infection.
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. The company is headquartered in Garden City, New York and currently employs 45 full-time employees. The company went IPO on 2019-05-07. The firm is engaged in developing a nitric oxide (NO) generator and delivery system through its LungFit platmorfm that is capable of generating NO from ambient air. Its pipeline includes LungFit PH designed to deliver a dosage of NO to the lungs for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN), LungFit PRO for the treatment of viral lung infections for adults, which is commonly caused by rhinovirus, respiratory syncytial virus (RSV) and influenza virus and LungFit GO for the treatment of rare and serious pulmonary disease associated with increased morbidity and mortality called Nontuberculous mycobacteria (NTM) lung infection.
Revenue Surge: Revenue for the quarter grew 105% year-over-year to $2.2 million, with sequential growth of 21%, reflecting ongoing adoption of LungFit PH.
Margins Improve: Gross profit turned positive to $300,000, up from a gross loss in both prior year and prior quarter.
Cost Discipline: Operating expenses fell 36% year-over-year to $6.9 million due to cost reductions, with SG&A down 42% and R&D down as Gen 2 development winds down.
Commercial Momentum: Over 45 hospitals now use LungFit PH; global distribution expanded to 40 countries, and first VA hospital sale achieved.
Second-Gen Pipeline: LungFit PH Gen 2 on track for anticipated FDA decision by end of 2026, with ongoing positive FDA interactions.
Balance Sheet Strengthened: Recent financings and sale of NeuroNOS subsidiary provide cash runway into 2027.
Strategic Focus: Gen 2 system designed to expand market and improve service intervals; company focused on continued commercial execution.
